DiaMedica Therapeutics Inc. - notizie pubblicate 174 - letture 1.760
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disord ...
DIAMEDICA THERAPEUTICS INC.
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: april 9, 2024 9:00 a.m. form: s-3 cik: 0 ...
DIAMEDICA THERAPEUTICS INC.
2023 Annual Report
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer diamedica therapeuti ...
DIAMEDICA THERAPEUTICS INC.
Proxy Statement - Form DEF 14A
Dmtp20240329_def14a.htm united states securities and exchange commission washington, d.c. 20549 schedule14a proxy statement pursuant to section 14(a) of the securities exchange act ...
DIAMEDICA THERAPEUTICS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer diamedica therapeutics inc. published ...
DIAMEDICA THERAPEUTICS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
Dmtp20230316_defa14a.htm united states securities and exchange commission washington, d.c. 20549 schedule 14a information proxy statement pursuant to section 14(a) of the securitie ...
DIAMEDICA THERAPEUTICS INC.
Registration Statement - Specified Transactions - Form S-3
Dmtp20240315_s3.htm as filed with the securities and exchange commission on march 21, 2024. registration no. 333- united states securities and exchange commission washington, d.c. ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Conference call and webcast march 20 at 8:00 am eastern time / 7:00 am central time remedy2 clinical site activation commenced in december 2023 strengthened management team with lo ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results - Form 8-K
Diamedica therapeutics provides a business update and announces full year 2023 financial results conference call and webcast march 20 at 8:00 am eastern time / 7:00 am central time ...
DIAMEDICA THERAPEUTICS INC.
Annual Report for Fiscal Year Ending --12-31, 2023 (Form 10-K)
Dmtp20231231_10k.htm united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securitie ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
Diamedica presents the protocol and rationale for remedy2, a pivotal trial in patients suffering acute ischemic stroke ineligible for tpa and/or mechanical thrombectomy minneapolis ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
DIAMEDICA THERAPEUTICS INC.
Initial Statement of Beneficial Ownership - Form 3
Ownership submission form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section ...
DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Executive with strong track record in advancing pipelines through clinical development minneapolis--(business wire)-- diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage b ...
DIAMEDICA THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti